US Court of Appeals Rules in Favor of Minerva Surgical and Denies Hologic Petition to Rehear Patent Invalidity Decision

Fusion Marketplace Changes Healthcare Traveler Experience

Fusion Marketplace is a traveler-first driven platform giving healthcare professionals the power to make decisions in their careers that they haven't been able to in the past.

Veranex Announces Investment From Summit Partners to Form Comprehensive Concept-to-Commercialization Medtech Services Company

As the first phase in building this global entity, Veranex has acquired three complementary solution providers: Ximedica, Quartesian, and Boston Healthcare Associates. By bringing these companies together, Veranex combines the industry’s key pillars of design and engineering, regulatory, clinical, and market access into a single-source solution.

Today Minerva Surgical announced today that the U.S. Court of Appeals for the Federal Circuit in Washington, D.C. (the “Federal Circuit”) issued its final Mandate, formally ending Hologic’s appeal and rejecting Hologic’s attempt to reverse its April 2019 decision concluding that Hologic’s ‘183 patent is invalid.  On July 16, 2019 the Federal Circuit had already denied Hologic’s Petition to reconsider its April decision.  Hologic asserted the ‘183 patent against Minerva in a 2015 lawsuit, after which Minerva successfully challenged the validity of the ‘183 patent.

Also, based on the Federal Circuit’s April decision that the ‘183 patent is invalid, in May the U.S Federal District Court for the District of Delaware (the “District Court”) issued an Order denying Hologic’s request to halt sales of Minerva’s Endometrial Ablation System based on the ‘183 patent.  In denying Hologic’s request, the District Court noted in its Order that: “It is not likely that the Federal Circuit will reconsider its decision or that the Supreme court will grant certiorari.”  As confirmed today by the Federal Circuit’s Mandate, the District Court’s prediction that the Federal Circuit was unlikely to reconsider its decision that the ‘183 patent is invalid proved to be correct.  Consequently, Minerva remains free to continue selling its best-in-class Minerva Endometrial Ablation System.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles